Finance

Lists
Why is SABS up ३.०६%?
Dive Deeper
SABS:NASDAQ
SAB Biotherapeutics Inc
US$ ३.०३
+३.०६%
(+०.०९०) 1D
US$ ३.०३
०.००% (०.००)
After hours
Closed: नोभेम्बर ६, १६:००:०० GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SABS...
Open
US$ २.९८
High
US$ ३.१४
Low
US$ २.९१
Mkt. cap
२७.५७ करोड
Avg. vol.
७.१४ लाख
Volume
३.०१ लाख
52-wk high
US$ ५.१५
52-wk low
US$ २.४४
EPS
-US$ ०.६३
Beta
०.६७
Shares outstanding
९.१० करोड
No. of employees
८६
Open
US$ २.९८
High
US$ ३.१४
Low
US$ २.९१
Mkt. cap
२७.५७ करोड
Avg. vol.
७.१४ लाख
Volume
३.०१ लाख
52-wk high
US$ ५.१५
52-wk low
US$ २.४४
EPS
-US$ ०.६३
Beta
०.६७
Shares outstanding
९.१० करोड
No. of employees
८६
News stories
From web sources and news partners
About SAB Biotherapeutics Inc
CEO-
Employees८६
Founded२०१४
HeadquartersMiami Beach, फ्लोरिडा, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Websitesab.bio
Analyst ratings
Based on 4 analysts giving stock ratings to SABS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for SABS in the last 3 months.
Highest
Current US$ ३.०३
US$ १५.०० (+३९५.०५%)
Average
US$ १३.२५ (+३३७.२९%)
Lowest
US$ ११.०० (+२६३.०४%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Oppenheimer
Buy
Reiterated
US$ १४.००
+३६२%
11/06/2026
Samantha Semenkow
Citi
Buy
Maintained
US$ ११.००
+२६३%
11/05/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
US$ १५.००
+३९५%
11/05/2026
Eliana Merle
Barclays
Buy
Maintained
US$ १३.००
+३२९%
11/06/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
US$ १०.००
+२३०%
08/06/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
US$ १६.००
+४२८.१%
06/16/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
US$ ६.००
+९८%
06/16/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
US$ १४.००
+३६२%
06/15/2026
Roger Song
Jefferies
Buy
Initiated
US$ ११.००
+२६३%
05/20/2026
Yatin Suneja
Guggenheim
Buy
Maintained
US$ १५.००
+३९५%
05/13/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
US$ १३.००
+३२९%
04/02/2026
Michael Yee
UBS
Buy
Maintained
US$ ७.००
+१३१%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
-
-
-
-
Cost of goods sold
९७.२८ लाख
१.३४ करोड
१.६२ करोड
-
Cost of revenue
९७.२८ लाख
१.३४ करोड
१.६२ करोड
-
Research and development expenses
-
-
-
१.८१ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
६०.४२ लाख
६६.०० लाख
७२.०५ लाख
७८.२२ लाख
Operating expense
६०.४२ लाख
६६.०० लाख
७२.०५ लाख
-
Total operating expenses
१.५८ करोड
२.०० करोड
२.३४ करोड
२.५९ करोड
Operating income
-१.५८ करोड
-२.०० करोड
-२.३४ करोड
-
Other non operating income
-१७.२८ लाख
१.४४ लाख
-७.६१ लाख
१९.९१ लाख
EBT including unusual items
-१.६९ करोड
-१.८९ करोड
-२.२५ करोड
-२.२३ करोड
EBT excluding unusual items
-१.६९ करोड
-१.८९ करोड
-२.२५ करोड
-२.२३ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.६९ करोड
-१.८९ करोड
-२.२५ करोड
-२.२३ करोड
Net profit margin
-
-
-
-
Earnings per share
-०.४१
-
-०.२८
-०.२६
Interest and investment income
७.०१ लाख
१०.४७ लाख
१७.०९ लाख
१६.०८ लाख
Interest expense
-६३.४६ हजार
-६२.७४ हजार
-६२.०० हजार
-
Net interest expenses
६.३७ लाख
९.८४ लाख
१६.४७ लाख
१६.०८ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.५० करोड
-१.९२ करोड
-२.२५ करोड
-२.५१ करोड
Gain or loss from assets sale
-
-
-
-६६.०० हजार
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू